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Abstract: This contribution reports the design, preparation, photophysical and photochemical
characterization, as well as a preliminary biological evaluation of mesoporous silica nanoparticles
(MSNs) covalently integrating a nitric oxide (NO) photodonor (NOPD) and a singlet oxygen (1O2)
photosensitizer (PS) and encapsulating the anticancer doxorubicin (DOX) in a noncovalent fashion.
These MSNs bind the NOPD mainly in their inner part and the PS in their outer part in order to
judiciously exploit the different diffusion radius of the cytotoxic NO and 1O2. Furthermore this silica
nanoconstruct has been devised in such a way to permit the selective excitation of the NOPD and the
PS with light sources of different energy in the visible window. We demonstrate that the individual
photochemical performances of the photoactive components of the MSNs are not mutually affected,
and remain unaltered even in the presence of DOX. As a result, the complete nanoconstruct is able to
deliver NO and 1O2 under blue and green light, respectively, and to release DOX under physiological
conditions. Preliminary biological results performed using A375 cancer cells show a good tolerability
of the functionalized MSNs in the dark and a potentiated activity of DOX upon irradiation, due to the
effect of the NO photoreleased.
Keywords: multimodal therapy; singlet oxygen; doxorubicin; nitric oxide
1. Introduction
Multimodal cancer therapy involves the use of two or more treatment modalities with the aim
to attack tumors on different sides by acting either on a single oncogenic pathway through different
mechanisms or across parallel pathways without amplification of side effects [1–4]. In this frame, the
combination of conventional chemotherapeutics with light-activated therapeutic treatments is a very
appealing approach to potentiate the therapeutic outcome through anticancer synergistic/additive
effects [5]. Light represents in fact as suitable and minimally invasive tool that permits the introduction
of therapeutic species in biological environments with superb spatiotemporal control [6]. Among
the light-activatable therapeutic treatments, photodynamic therapy (PDT) is so far one of the most
promising to combat cancer diseases [7]. This treatment modality mainly exploits the cytotoxic effects
of the highly reactive singlet oxygen (1O2), catalytically generated by energy transfer between the
long-lived excited triplet state of a photosensitizer (PS) and the nearby molecular oxygen [8].
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Another emerging light-activated approach is based on the photoregulated release of nitric oxide
(NO) through the use of NO photodonors (NOPD) [9–11]. Although still confined to the research area,
this NO-based PDT, namely NOPDT, has come to the limelight in recent years and holds very promising
features in cancer treatment [12]. In fact, apart from playing multiple roles in the bioregulation of a
broad array of physiological processes [13], NO has also proven to be an effective anticancer agent. If
generated in an appropriate concentration range [14,15] this diatomic free radical can act not only as a
cytotoxic agent [16], but also as inhibitor of the ATP binding cassette (ABC) transporters responsible
of the efflux of chemotherapeutics and of the induction of multidrug resistance (MDR) in cancer
cells [17,18]. In contrast to the photocatalytic mechanism leading to 1O2 in PDT, the working principle
of NOPDT exploits the excitation light to uncage NO leading, of course, to a consumption of the
NOPD [9–11]. Noteworthy, both 1O2 and NO are multitarget species that have not a reduced efficacy in
MDR cells due to their short lifetimes, and confine their action to short distances from the production
site inside the cells (<20 nm for 1O2 and <200 µm for NO), reducing systemic toxicity issues common
to many conventional drugs. Besides, since NO photorelease is independent of O2 availability, it may
successfully complement PDT at the onset of hypoxic conditions, typical for some tumors, where PDT
may fail [19].
The significant breakthroughs in nanomedicine permit nowadays the development of
multifunctional platforms in which more therapeutic agents are entrapped in a single nanocarrier.
This offers an unprecedented opportunity to devise a better scheme for precise and controlled
delivery of multiple therapeutics to the same area of the body at a predefined extra/intracellular
level [20–23]. In this context, nanoplatforms combining PDT and NOPDT are opening new horizons
towards more effective and less invasive cancer treatments entirely based on “nonconventional”
chemotherapeutics [24]. Besides, an increasing large number of nanoconstructs in which PDT has
been combined with chemotherapy in the management of several cancer types has been reported
in literature [5]. In contrast, only recently NOPDT has been successfully used in combination with
chemotherapeutics [25]. Based on this scenario, the achievement of a trimodal nanoplatform able
to generate 1O2 and NO and, simultaneously, to deliver a conventional chemotherapeutic is a very
challenging objective to pursue. Mesoporous silica nanoparticles (MSNs) are very suitable scaffolds to
this end due to their high loading capacity, ease of surface functionalization, good biocompatibility,
and satisfactory light transparency [26–30]. Moreover these inorganic scaffolds have been extensively
used as excellent carrier for (i) conventional chemotherapeutics to reverse MDR [31], (ii) PDT agents
alone and in combinations with chemotherapeutics [32–34], and (iii) spontaneous NO donors [35] and
NOPD [36].
In this manuscript, we report the first example of engineered MSNs able to deliver “three
bullets” for potential anticancer therapy. These MSNs covalently integrate in their molecular scaffold
erythrosine and a nitroaniline derivative as suitable PS and NOPD, respectively, and encapsulate the
chemotherapeutic doxorubicin (DOX) in a noncovalent fashion. We demonstrate that the photochemical
properties of the PS and NOPD are preserved in an excellent manner in the MSNs containing all active
components. As a result, the spontaneous release of DOX under physiological conditions can be
combined with the photoregulated generation of 1O2, NO, or both by using light stimuli of appropriate
energy in the visible light range.
2. Materials and Methods
2.1. Materials
All reagents (Sigma-Aldrich, Saint Louis, MO, USA) were of high commercial grade and were
used without further purification. All solvents used (from Carlo Erba, Val de Reuil, France) were
spectrophotometric grade. The free NOPD was synthesized according to our previously published
procedure [37].
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2.2. Synthetic Procedures
2.2.1. Synthesis of Amino-Modified MSNs (MSNs-NH2)
MSNs-NH2 were prepared according to literature procedures using cetyltrimethylammonium
bromide (CTAB) as template [38]. Briefly, CTAB (1.9 mmoL) was dissolved in 340 mL of water followed
by the addition of 2.45 mL of NaOH (2.0 mol L−1). The temperature was adjusted at 80 ◦C and
tetraethoxy silane (TEOS), 3.5 mL, 18.1 mmoL, and 3-aminopropyl triethoxy silane (APTES), (0.43 mL,
2.04 mmol) were simultaneously added dropwise to the solution during 4 min. The mixture was stirred
at 80 ◦C for 2 h to give rise to white precipitate. The solid product was filtered, washed with deionized
water and ethanol, and dried at 60 ◦C for 24 h.
2.2.2. Synthesis of the PS-Modified MSNs (PS-MSNs)
500 mg of MSNs-NH2 were added in 15 mL of DMF and sonicated (90 s, 42 KHz). Then PS
erythrosine (27 mg, 1 eq), O-(7-Azabenzotriazol-1-yl)-1,1,3,3-tetramethyl uronium hexafluorophosphate
(11.1 mg, 1 eq) and N,N-di-isopropiletilamine (10 µL, 2 eq) were added to the suspension. The mixture
was stirred at room temperature for 24 h under dark conditions. The solid product was filtered, washed
with DMF (4 portions of 5 mL) and dried at 60 ◦C for 24 h. PS-MSNs were prepared with the nominal
concentration of ca. 0.03% (w/w) of PS. The real concentration of the PS was indirectly determined by
UV–Vis spectrum of the eluate (post washing) using ε543 = 112.000 M−1 cm−1 in DMF.
2.2.3. Synthesis of NOPD-Modified PS-MSNs (PS-MSNs-NOPD)
One-hundred milligrams of PS-MSNs was added in 10 mL of DMSO and sonicated (90 s, 50 KHz).
Then cesium carbonate (10 mg, 0.2 eq) and 4-chloro-1-nitro-2(trifluoromethyl) benzene (30 µL, 2 eq)
were added and refluxed overnight. The solid product was filtered and washed with ethyl acetate
(to remove the unbounded 4-chloro-1-nitro-2(trifluoromethyl) benzene) and water (to remove the
excess of cesium carbonate) and dried under vacuum to obtain PS-MSNs-NOPD. PS-MSNs-NOPD
were prepared with the nominal concentration of ca. 0.4% (w/w) of NOPD. The real concentration
of the NOPD was indirectly determined by UV–Vis spectrum of the eluate (post washing) using
ε400 = 10.000 M−1 cm−1 in water.
2.2.4. Stability of the PS-MSNs-NOPD
Representative samples of PS-MSNs-NOPD (1 mg mL−1) were either sonicated for 1 h or stirred
at 70 ◦C for 2 h in the dark. Afterwards the samples were centrifuged for 25 min and the supernatant
was collected and analyzed by UV-VIS absorption. The absence of any relevant absorption between
250 and 800 nm, suggested that no leaching of the chromogenic units from the MSN scaffold occurs.
2.3. Instrumentation
Transmission electron microscopy (TEM) experiments were performed with a TEM JEOL JEM-2010
(Pleasanton, CA, USA) using the bright field in conventional parallel beam (CTEM) mode (BF).
The X-ray diffraction analysis were done at the Complexo de Apoio à Pesquisa (COMCAP/UEM)
in Bruke diffractometer model D8 Advance with radiation Cu-Kα (λ = 1.54062 Å). The scanning was
done from 1 to 10◦ of 2θwith 0.45◦/min.
UV-Vis spectra absorption and fluorescence emission spectra were recorded with a JascoV-560
spectrophotometer (Easton, MD, USA) and a Spex Fluorolog-2 (mod. F-111) spectrofluorimeter,
respectively, in air-equilibrated solutions, using either quartz cells with a path length of 1 cm.
Fluorescence lifetimes were recorded with the same fluorimeter equipped with a TCSPC Triple
Illuminator (Kyoto, Japan). The samples were irradiated by a pulsed diode excitation source (Nanoled)
at 455 nm and the decays were monitored at 500 nm. The system allowed measurement of fluorescence
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lifetimes from 200 ps. The multiexponential fit of the fluorescence decay was obtained using the
following equation.
I(t) =
∑
αI exp(−t/τi)
Absorption spectral changes were monitored by irradiating the sample in a thermostated quartz
cell (1 cm path length, 3 mL capacity) under gentle stirring, using a continuum laser with λexc = 405 nm
and λexc = 532 nm (ca. 100 mW) and having a beam diameter of ca. 1.5 mm for the excitation of the
NOPD and the PS, respectively.
Direct monitoring of NO release in solution was performed by amperometric detection (World
Precision Instruments, Sarasota, FL, USA), with a ISO-NO meter, equipped with a data acquisition
system, and based on direct amperometric detection of NO with short response time (<5 s) and
sensitivity range 1 nM to 20 µM. The analogue signal was digitalized with a four-channel recording
system and transferred to a PC. The sensor was accurately calibrated by mixing standard solutions of
NaNO2 with 0.1 M H2SO4 and 0.1 M KI according to the following reaction.
4H+ + 2I− + 2NO2−→ 2H2O + 2NO + I2
Irradiation was performed in a thermostated quartz cell (1 cm path length, 3 mL capacity) using
the continuum laser with λexc = 405 nm. NO measurements were carried out under stirring with the
electrode positioned outside the light path in order to avoid NO signal artifacts due to photoelectric
interference on the ISO-NO electrode.
2.4. Chemical Detection of NO
NO release was also measured indirectly by means of the well-known, highly sensitive (detection
limit on the order of the picomoles) fluorimetric bioassay of Misko et al. [39] based on the ring closure of
the nonfluorescent 2,3-diaminonaphthalene (DAN) with nitrite to form the highly fluorescent product
2,3-diaminonaphthotriazole (DANT). Aliquots of 2 mL of aqueous suspension of the desired MSNs
were irradiated or kept in the dark. Afterwards, the samples were centrifuged by 25 min and 1 mL
of the supernatant was collected. One-hundred microliters of DAN solution (DAN 0.30 M in 0.62 M
HCl) was added to 1 mL of the supernatant and solutions were stirred for 20 min at room temperature.
Three-hundred microliters of NaOH 3 M was added in previous solution and stirred for 20 min at
room temperature. The resultant solution was put into the fluorescent cuvette and the fluorescence
was recorded at λexc = 360 nm.
2.5. Chemical Detection of Singlet Oxygen
The release of 1O2 by the MSNs was determined by indirect measurements using the well-established
traps of 1O2 such as 1,3-diphenylisobenzofuran (DPBF) [40] and p-nitrosodimethylaniline/histidine
(RNO/His) [41] in ethanol and phosphate buffer (pH = 7.4), respectively. The reaction between the
scavengers and 1O2 can be followed by the UV-Vis absorption by monitoring the bleaching of the traps at
400 nm and 440 nm in the case of DPBF and RNO/His, respectively. The free PS in ethanol or in PBS was
used as standard and the 1O2 delivery efficiency (η∆) can be calculated by the equation the following
equation [42].
η∆particle = ΦERY
tERY
tparticle
Briefly, the scavenger is transferred into a suspension of the nanoparticle (1 mg mL−1) or a solution
containing the PS and, under constantly stirring, irradiated at time intervals. In order to avoid intense
scattering the spectrum was registered after the deposition of the particles on the bottom of cuvette.
The absorptions of both solutions were normalized at 532 nm assuming that the real absorption of the
PS bounded in the MSNs can be calculated by measuring the absorption spectrum of a suspension of
PS-MSNs and subtracting the baseline scattering by multiple point level baseline correction.
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2.6. Loading and Release of DOX
Four-and-a-half micrograms of PS-MSNs-NOPD was mixed with 4.0 mL of PBS (pH = 7.4)
containing DOX (220 µM). After stirring for 24 h, in the dark and at room temperature, the DOX-loaded
PS-MSNs-NOPD (PS-MSNs-NOPD/DOX) were collected by centrifugation. The samples were washed
with PBS and the content of the DOX was determined by comparison between the absorbance of the
supernatant and the original solution at 482 nm (ε482 = 10.000 M−1 cm−1). A dispersion containing
1 mg of PS-MSNs-NOPD/DOX in 2.0 mL of PBS (pH 7.4) was incubated at 37 ◦C, in the dark under
continuous stirring. At specified time, 100 µL of the supernatant was taken out after centrifugation
(15,000× g rpm for 2 min) and an equal volume of fresh PBS was added to keep the sink condition. The
concentration was determined by reading the fluorescence emission of DOX at 594 nm.
2.7. Biological Assays
2.7.1. Cells Characterization
Human melanoma A375 cells (ATCC, Manassas, VA, USA) were maintained in DMEM medium
supplemented with 10% v/v fetal bovine serum, 1% v/v penicillin-streptomycin, 1% v/v l-glutamine.
Cells were maintained in a humidified atmosphere at 37 ◦C, 5% CO2. To measure the expression of ABC
transporters, 1× 106 cells were rinsed and fixed with 2%w/v paraformaldehyde (PFA) for 2 min, washed
three times with PBS and stained with anti-P-glycoprotein (Pgp/ABCB1) (Kamiya, Hamamatsu City,
Japan), anti-MDR-related protein 1 (MRP1/ABCC1) (Abcam, Cambridge, UK) and anti-breast cancer
resistance protein (BCRP/ABCG2) (SantaCruz Biotechnology Inc., Santa Cruz, CA, USA) antibodies for
1 h on ice, followed by an AlexaFluor 488-conjugated secondary antibody (Millipore, Billerica, MA,
USA) for 30 min. One-hundred-thousand cells were analyzed with EasyCyte Guava™ flow cytometer
(Millipore), equipped with the InCyte software (Millipore). Control experiments included incubation
with non-immune isotype antibody.
2.7.2. Viability Assays
Cells were incubated for 4 h with the different MSNs samples (1 mg mL−1). Cells were maintained
in the dark or irradiated at room temperature for 30 min with a blue LED at 400 nm with an irradiance
of 1.75 mW/cm2; irradiance was measured with a Delta Ohm HD2302.0 lightmeter equipped with a
Delta Ohm LP4771RAD light probe. Twenty-four hours after the irradiation, cells were stained with
5% w/v crystal violet aqueous solution in 66% v/v methanol, washed twice with water, solubilized with
10% v/v acetic acid. The absorbance was read at 570 nm, using a Packard EL340 microplate reader
(Bio-Tek Instruments, Winooski, VT, USA). The absorbance of untreated cells was considered as 100%
viability; the results were expressed as percentage of viable cells versus untreated cells.
2.7.3. Statistical Analysis
Data are provided as means ± SD. The results were analyzed by a one-way ANOVA and Tukey’s
test. p < 0.05 was considered significant.
3. Results and Discussion
Scheme 1 illustrates the “three-bullets” MSNs with their working principle, and the rationale
behind their design is described in the following.
Nanomaterials 2019, 9, 823 6 of 14
Nanomaterials 2019, 9, x FOR PEER REVIEW 6 of 14 
 
Afterwards, most of the CTAB was eliminated by the pores allowing the covalent integration of the 
NOPD mainly therein, according with the procedure described in the experimental. 
An important issue to be addressed in the fabrication of phototherapeutic systems aimed at 
exploiting the effects of 1O2 and NO, regards the relative concentration of these species generated 
upon light excitation. As outlined above, 1O2 is produced through a photocatalytic process that, in 
principle, does not consume the PS, whereas photogeneration of NO occurs through a neat 
photochemical reaction with consequent consumption of the NOPD. As a consequence, the 
regulation of the reservoir of NO with respect to 1O2 is a critical point to be considered in view of an 
effective bimodal photodynamic action. This can be accomplished by (i) using a larger amount of the 
NOPD with respect to the PS, (ii) using PS and NOPD preferentially absorbing in different spectral 
regions, or (iii) combining both conditions. The appropriate synthetic protocol for the anchoring of 
the PS and NOPD permits to fulfill the first condition due to the regulation of the relative 
concentrations of distinct subsets of chromogenic units integrated within the very same scaffold. For 
such a reason, the amount of NOPD bounded to the MSNs was much larger than the PS (0.4% vs. 
0.03%). Besides, the appropriate selection of the excitation wavelengths fulfills the second condition. 
On this basis, one can realize that the choice of erythrosine as PS and the nitroaniline derivative as 
NOPD is, of course, not casual. In fact, as shown in the spectra reported in Scheme 1, these two 
photoprecursors absorb in distinct regions of the visible spectral range and therefore can be 
selectively or simultaneously excited by using blue light, green light or both. 
 
Scheme 1. Schematic for the “three-bullets” PS-MSNs-NOPD/DOX and their working principle. The 
molecular structures of the free photosensitizer (PS) and the nitric oxide photodonor (NOPD) and 
their normalized absorption spectra in PBS (10 mM, pH 7.4) are also shown. 
PS-MSNs were characterized by X-ray powder diffraction (XRD), TEM, and energy-dispersive 
X-ray spectroscopy (EDX) analysis in order to verify their structural parameters and particle size. 
Figure 1A shows the diffractograms for the original material (MSNs) as well for the functionalized 
PS-MSNs. The typical reflections at 100, 110, 200, and 210 (not well resolved) confirm the production 
of an ordered hexagonal network material. The covalent addition of the PS did not affect the 
structural integrity of the material. The shift to higher values of 2θ can indicate a contraction of the 
porous due to the condensation of the sylanol groups. TEM microscopy (Figure 1B) shows particles 
with reasonable homogeneity regarding size and shape having an average size around 100 nm. EDX 
analysis (Figure 1C) confirms the anchoring of the PS by the signal of iodide in the external surface. 
Scheme 1. Schematic for the “three-bullets” PS-MSNs-NOPD/DOX and their working principle. The
molecular structures of the free photosensitizer (PS) and the nitric oxide photodonor (NOPD) and their
normalized absorption spectra in PBS (10 mM, pH 7.4) are also shown.
As outlined in the introduction, 1O2 and NO have diffusion radius of <20 nm and <200 µm,
respectively, due to their short lifetimes: ca. 3 µs for 1O2 [43] and ca. 5 s for NO [12]. Taking this into
account we designed the MSNs in order to integrate mainly the PS in the outer part of the scaffold
and the NOPD in the inner pores. This strategy avoids that 1O2 decays before to get out from the
scaffold. On the other hand, despite being photogenerated in the core of the scaffold NO can diffuse
out due to its longer lifetime. To this end, initially we synthesized the PS-MSNs before to eliminate
the CTAB template (see experimental) from the amino terminated MSNs-NH2. In such a way, most
of the condensation reaction between MSNs-NH2 and the free PS takes place at the scaffold surface.
Afterwards, most of the CTAB was eliminated by the pores allowing the covalent integration of the
NOPD mainly therein, according with the procedure described in the experimental.
An important issue to be addressed in the fabrication of phototherapeutic systems aimed at
exploiting the effects of 1O2 and NO, regards the relative concentration of these species generated upon
light excitation. As outlined above, 1O2 is produced through a photocatalytic process that, in principle,
does not consume the PS, whereas photogeneration of NO occurs through a neat photochemical reaction
with consequent consumption of the NOPD. As a consequence, the regulation of the reservoir of NO
with respect to 1O2 is a critical point to be considered in view of an effective bimodal photodynamic
action. This can be accomplished by (i) using a larger amount of the NOPD with respect to the PS,
(ii) using PS and NOPD preferentially absorbing in different spectral regions, or (iii) combining both
conditions. The appropriate synthetic protocol for the anchoring of the PS and NOPD permits to fulfill
the first condition due to the regulation of the relative concentrations of distinct subsets of chromogenic
units integrated within the very same scaffold. For such a reason, the amount of NOPD bounded to
the MSNs was much larger than the PS (0.4% vs. 0.03%). Besides, the appropriate selection of the
excitation wavelengths fulfills the second condition. On this basis, one can realize that the choice of
erythrosine as PS and the nitroaniline derivative as NOPD is, of course, not casual. In fact, as shown in
the spectra reported in Scheme 1, these two photoprecursors absorb in distinct regions of the visible
spectral range and therefore can be selectively or simultaneously excited by using blue light, green
light or both.
PS-MSNs were characterized by X-ray powder diffraction (XRD), TEM, and energy-dispersive
X-ray spectroscopy (EDX) analysis in order to verify their structural parameters and particle size.
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Figure 1A shows the diffractograms for the original material (MSNs) as well for the functionalized
PS-MSNs. The typical reflections at 100, 110, 200, and 210 (not well resolved) confirm the production
of an ordered hexagonal network material. The covalent addition of the PS did not affect the structural
integrity of the material. The shift to higher values of 2θ can indicate a contraction of the porous
due to the condensation of the sylanol groups. TEM microscopy (Figure 1B) shows particles with
reasonable homogeneity regarding size and shape having an average size around 100 nm. EDX analysis
(Figure 1C) confirms the anchoring of the PS by the signal of iodide in the external surface.
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Figure 1. (A) X-ray powder diffraction (XRD) patterns of mesoporous silica nanoparticles (MSNs)
(black line) and PS-MSNs (red line). (B) Representative TEM images and (C) EDX analysis of the
PS-MSNs. The inset B shows a homogeneous distribution of the nanoparticles and the inset of C shows
a zoom in the region of the iodide cluster.
The binding of the PS to the MSNs was further confirmed by the absorption and fluorescence
emission spectra of the PS-MSNs (Figure 2). The aqueous suspension of PS-MSNs shows the
characteristic absorption of the PS at 537 nm, slightly red-shifted with respect to that of unbounded PS
(see absorption spectrum in Scheme 1), and its typical fluorescence emission in the green region with
maximum at ca. 550 nm.
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The covalent binding of the NOPD mainly in the inner part of the MSNs does not preclude
their capability to encapsulate in a noncovalent fashion additional therapeutic compounds. As a
proof of principle, we selected Doxorubicin (DOX) as a suitable chemotherapeutic. This drug has
a wide spectrum of activity in clinical application but it has to face the development of MDR in
cancer cells [45]. The ABC transporters Pgp/ABCB1, MRP1/ABCC1 and BCRP/ABCG2 are the main
transporters effluxing DOX from tumor cells [46]. The spectrum shown in Figure 4A clearly shows the
effective encapsulation of DOX within the PS-MSNs-NOPD. In fact, the absorption band of the NOPD
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is accompanied by the characteristic band of the DOX with maximum at ca. 488 nm (see spectrum of
the free DOX in Figure 4, for sake of comparison). DOX encapsulation was further confirmed by the
appearance of its typical fluorescence emission in the red region (Figure 4B). Due to the scattering of the
silica scaffold, the emission efficiency of the encapsulated DOX can be only estimated, resulting in ~70%
smaller than the free drug. However, the biexponential decay observed for the PS-MSNs-NOPD/DOX
(see inset Figure 4B) gave lifetimes of 0.54 and 2.1 ns, which were basically the same to those observed
for the free DOX. These findings probably suggest the presence of some either non-emissive or scarcely
emissive aggregates of DOX (these latter with lifetime below our time-resolution window) within the
pores of the silica scaffold. The percentage of the DOX incorporated was ca. 85% corresponding to
90 µg of DOX per mg of MSNs
In order to demonstrate the validity of the “three bullets” MSNs, we performed 1O2 and NO
measurements under green and blue light stimuli, respectively, and DOX release experiments at 37 ◦C.
In this case, we used p-nitrosodimethylaniline/histidine (RNO/His), a well-known 1O2 scavenger in
aqueous PBS. In fact, in contrast to the previously used DPBF, RNO absorption maximum is at ca.
440 nm and thus is less affected by the absorption of the NOPD unit. Figure 5A shows the evolution
of the absorbance bleaching for the unfunctionalized MSNs, those integrating only PS, both PS and
NOPD, and the complete nanoplatform also loading DOX. The bleaching monitored at 440 nm upon
532 nm light excitation was observed in all samples containing the PS and provides a clear cut evidence
for the delivery of 1O2, in contrast to the result observed for the unfunctionalized MSNs. Interestingly,
the efficiency for the 1O2 observed in the case of the complete system PS-MSNs-NOPD/DOX was
basically comparable with the samples not loaded with DOX and not containing the NOPD, suggesting
that the copresence of the NOPD and DOX does not influence the photophysical properties of the
bound PS.Nanomaterials 2019, 9, x FOR PEER REVIEW 10 of 14 
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PS-MSNs-NOP /DOX uspension (1 mg mL−1) in PBS (pH 7.4, 10 mM) at 37 ◦C.
The NO photorelease properties of PS-MSNs-NOPD/DOX were unambiguously demonstrated by
direct real-time monitoring using an ultrasensitive NO electrode, which directly detects NO with nM
concentration sensitivity employing an amperometric technique. The results illustrated in Figure 5B
provide evidence that the nanoconstruct is stable in the dark, whereas it releases NO upon blue light
excitation at 405 nm, stops as the light is turned off, and restarts again upon illumination. Also in
this case, a comparison with the sample not loaded with DOX, confirmed that the efficiency of the
NO photorelease is basically not affected by the presence of the chemodrug. NO photorelease was
further proved by the indirect DAN assay (see experimental), one of the most sensitive and selective
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fluorescence-based methods for NO detection as nitrite (see experimental). As evident from the inset
of Figure 5B, the significant fluorescence for of the nitrite probe was observed only in the case of the
irradiated samples.
DOX release from the nanoparticles was performed under sink conditions at 37 ◦C in PBS at pH
7.4. Figure 5C illustrates the releasing profile of the DOX monitored for 24 h. After 3 h, ca. 10% of DOX
was released suggesting that the presence of the NOPD and the PS in the silica scaffold do not change
the typical release profile of DOX. Note that the amount of released chemodrug is comparable with
that observed for DOX in similar MSN scaffolds [34].
As outlined in the introductory part, NO may play a double role when combined with
chemotherapeutics. It can increase the therapeutic effectiveness of a chemodrug by acting as
cytotoxic agent itself, if produced at significant concentrations, but also by inhibiting the ABC
transporters responsible for MDR, when generated in non-toxic amount. Therefore, we considered it
useful to perform some very preliminary biological experiments by using A375 melanoma cell line,
overexpressing Pgp, MRP1, and BCRP (Figure 6), i.e., the main pumps effluxing DOX.
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Figure 6. Representative histograms of Pgp/ABCB1, MRP1/ABCC1, and BCRP/ABCG2 surface levels
in A375 cells, measured by flow cytometry in duplicate. The figure is representative of 1 out of 3
experiments with similar results.
Thanks to the logical design of the MSNs, irradiation with blue light permits the selective excitation
of the NOPD component, ruling out any participation of 1O2 (which would require green light excitation
of the PS) in the cell viability. Figure 7 shows that the different samples of MSNs are well tol rated in
the dark and th t only a slight toxicity was observed upon blue light irradiation. Moreover, the very
moderate phototoxicity observed in the sample with NOPD (PS-MSNs-NOPD) is basically the same to
that of the sample, which does not integrate the NOPD (PS-MSNs/DOX), suggesting that under these
experimental conditions NO is produced at not toxic doses.
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presented as means ± SD (n = 3 independent experiments). * p < 0.02: vs. Ctrl, irradiated cells (light);
◦ p < 0.05: PS-MSNs-NOPD/DOX vs. PS-MSNs-NOPD and PS-MSNs/DOX.
Nanomaterials 2019, 9, 823 11 of 14
Interestingly, irradiation of the whole nanoconstruct (PS-MSNs-NOPD/DOX) increases cytotoxicity.
PS-MSNs-NOPD/DOX reduced cell viability more than PS-MSNs-NOPD and PS-MSNs/DOX,
suggesting that the presence of NOPD enhances the efficacy of DOX. We believe that such effect
can be tentatively attributed to the inhibition of the ABC transporters present on A375 cells by
NO photogenerated, an event already observed in melanoma cells treated with free NOPD/DOX
hybrids [25].
4. Conclusions
We have designed, synthesized and characterized a novel “three bullet” nanoconstruct based
on mesoporous silica nanoparticles for potential combined cancer photo-chemotherapy. Such a
multifunctional nanoplatform is able to generate 1O2 and NO under selective excitation with green and
blue light, respectively, and release the noncovalently entrapped anticancer DOX under physiological
conditions. A remarkable advantage of this system is the excellent preservation of the photochemical
properties of the active components once simultaneously integrated in the same scaffold and despite
the copresence of the DOX. This is the result of the strategy adopted which permitted to integrate the
PS and the NOPD in the outer and the inner sites of the nanoscaffold, avoiding potential and undesired
intermolecular photoprocesses (i.e., energy/electron transfer) which would have otherwise precluded
the final goal. This allows the individual photoactivable components to be operated either singularly
or in tandem upon the appropriate choice of the excitation wavelengths. At this regard, preliminary
biological results performed on A375 cells expressing ABC transporters show a potentiated activity
of DOX incorporated in our “three bullet” nanoconstruct upon irradiation with blue light, due to
the effect of the NO photoreleased. Note that the reduction of the cell viability observed under light
excitation (ca. 50%) is considered effective in overcoming DOX-resistance in cells expressing ABC
transporters [47,48], as those used in the present work. Besides its efficacy, a plus of our approach is
the absence of toxicity exerted by PS-MSNs/NOPD/DOX in the absence of irradiation. Since light can
be easily controlled and directed towards tumor tissue, in a translational perspective, our approach can
be considered a tumor-selective strategy that avoids undesired toxicity on nontransformed tissues and
overcomes a severe limitation of currently used chemotherapy. Detailed photobiological investigations
addressed to elucidate the single and the combined effects of all the active species produced by this
novel multifunctional drug delivery system are currently under investigation in our laboratories.
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